Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by Hellenic Cardiovascular Research Society.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Bayer
Information provided by:
Hellenic Cardiovascular Research Society
ClinicalTrials.gov Identifier:
NCT01317602
First received: March 16, 2011
Last updated: April 12, 2011
Last verified: April 2011

March 16, 2011
April 12, 2011
March 2011
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01317602 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study

This is a multicenter, 1-year prospective, observational study of Atrial Fibrillation (AF) in Greece, designed to provide real world data regarding the characteristics of AF patients in Greece, as well as current clinical practices and adherence to the 2010 ESC guidelines.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

The MANAGE-AF study will enroll 600 consecutive patients from the emergency cardiology departments and outpatient clinics in about 35 Greek hospitals. Their selection will be made in an effort to recruit a representative sample of patients from different geographic areas and stratums of the country.

Atrial Fibrillation
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
600
Not Provided
Not Provided

Inclusion Criteria:

  1. Patients aged ≥ 18 years with any type of AF(first diagnosed, paroxysmal, persistent, long-standing persistent and permanent) according to the classification described in the recent ESC guidelines.
  2. All patients should give written informed consent to participate in the study.

Exclusion Criteria:

  1. Patients anticipated life expectancy less than 1 year due to a severe concomitant disease.
  2. Participation in an another clinical trial, with the exception of epidemiology trials (observational) that do not influence AF management.
  3. Patients with mental disability unable to comply with follow - up visits and these who are unable to provide, in written, their informed consent or patients with anticipated inability to adhere to scheduled follow up visits.
Both
18 Years and older
No
Contact: Panos E. Vardas +302106723827 cro@cardioresearch.net
Greece
 
NCT01317602
HellenicCardiovascularRS
No
Katerina Roumeliotou, Hellenic Cardiovascular Research Society
Hellenic Cardiovascular Research Society
Bayer
Principal Investigator: Panos E. Vardas, MD, FESC, FACC President, Hellenic Cardiovascular Research Society
Hellenic Cardiovascular Research Society
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP